{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-020843","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.495305+00:00","generated_at":"2026-06-02T18:55:06.279863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bioventus Q1 revenue $129.5M (+8.7% YoY), guides FY24 higher","bullets":["Net loss from continuing ops $6.0M vs $100.0M prior year; diluted loss per share $0.07 vs $1.28.","Pain Treatments revenue $56.7M (+23.5% US); Surgical Solutions revenue $42.3M (+19.0% US).","Adjusted EBITDA $22.6M, up 33.5% YoY; adjusted gross margin expanded 190 bps.","FY 2024 guidance raised: net sales $535-550M, Adj. EBITDA $94-99M, Non-GAAP EPS $0.25-0.33.","Organic revenue growth 15.3% driven by Pain Treatments and Surgical Solutions."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-020843","json":"https://secwatch.observer/filing/0001628280-24-020843.json","markdown":"https://secwatch.observer/filing/0001628280-24-020843.md","text":"https://secwatch.observer/filing/0001628280-24-020843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/0001628280-24-020843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/bvs-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:55:06.279863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"368a07c987813452c5b15c6bdb791fc0152f7c29","claim":"Bioventus Inc. reported three months ended March 30, 2024 results: revenue $129.5 million, net income net loss from continuing operations of $6.0 million, EPS Loss per share of Class A common stock from continuing operations was $0.07.","evidence_excerpt":"For the first quarter, worldwide revenue totaled $129.5 million, an increase of 8.7% compared to the prior-year period. On an organic* basis, revenue increased 15.3%, driven by growth in Pain Treatments and Surgical Solutions. The Company also reported a first quarter net loss from continuing operations of $6.0 million, compared to a net loss from continuing operations of $100.0 million in the prior-year period. Adjusted EBITDA* from continuing operations totaled $22.6 million, advancing 33.5%, compared to the prior year total of $17.0 million due to strong revenue growth and increased gross margin. Loss per share of Class A common stock from continuing operations was $0.07 in the first quarter, compared to a loss of $1.28 in the prior-year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/0001628280-24-020843-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 30, 2024"},{"label":"Revenue","value":"$129.5 million"},{"label":"Net income","value":"net loss from continuing operations of $6.0 million"},{"label":"EPS","value":"Loss per share of Class A common stock from continuing operations was $0.07"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"816227e3b317eb35a64c9e768423b7cd9eb5a4c3","claim":"Bioventus Inc. reported full-year 2024 results: revenue $535 million to $550 million, EPS $0.25 to $0.33. Guidance raised.","evidence_excerpt":"Based on strong execution and significant momentum across the business, Bioventus is raising financial guidance for full-year 2024. The Company now expects: • Net sales of $535 million to $550 million—An increase of $15 million from previous guidance • Adjusted EBITDA* of $94 million to $99 million—An increase of $5 million from previous guidance • Non-GAAP EPS* of $0.25 to $0.33—An increase of $0.13 from previous guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/0001628280-24-020843-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2024"},{"label":"Revenue","value":"$535 million to $550 million"},{"label":"EPS","value":"$0.25 to $0.33"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}